| Name | Title | Contact Details |
|---|
Affigen was founded in 2016 by Frameshift, a firm that ideates, translates and launches life sciences companies that have the potential to fundamentally shift the metabolic rate of the industry. In February 2017, Affigen completed its Series A funding, led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC. Black Beret Life Sciences is the life sciences investment management arm of the Houston-based Bosarge Family Office. The firm was established in 2014 by Dr. Ed Bosarge to organize and manage investments in potentially game-changing technologies and companies in areas related to regenerative medicine, anti-aging and immunotherapy. Black Beret Life Sciences’ portfolio of managed investments includes companies and research across an array of disease areas, including diabetes, neurodegeneration, osteoarthritis, cancer immunotherapy and various conditions related to aging.
Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.
We are working to methodically engineer durable gene therapies for people with devastating diseases.
Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease.
Immunitas Therapeutics is a single cell genomics-based drug discovery company.